Lineage Cell Therapeutics (LCTX) Non-Current Assets (2010 - 2026)

Lineage Cell Therapeutics (LCTX) has 17 years of Non-Current Assets data on file, last reported at $53.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 13.6% year-over-year to $53.4 million; the trailing twelve-month figure through Mar 2026 stood at $201.1 million (down 19.09% YoY), and the FY2025 full-year result was $53.4 million, down 14.13% from the prior year.
• Non-Current Assets for Q1 2026 stood at $53.4 million, roughly flat from $53.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $63.6 million in Q1 2023 and bottomed at $5.7 million in Q4 2022.
• The 5-year median for Non-Current Assets is $62.2 million (2024), against an average of $56.3 million.
• The widest annual swing landed in 2023, when Non-Current Assets surged 1003.08%; it then retreated 24.77% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $5.7 million in 2022, then soared by 1003.08% to $62.6 million in 2023, then retreated by 0.57% to $62.2 million in 2024, then dropped by 14.13% to $53.4 million in 2025, then slipped by 0.11% to $53.4 million in 2026.
• The last three Non-Current Assets figures came in at $53.4 million (Q1 2026), $53.4 million (Q4 2025), and $47.4 million (Q3 2025), per Business Quant data.

Peer Comparison